Shawn Noronha, Electron Kebebew, Myriem Boufraqech
{"title":"Anaplastic thyroid cancer: genomic landscape, molecular drivers and novel therapeutics.","authors":"Shawn Noronha, Electron Kebebew, Myriem Boufraqech","doi":"10.1038/s41574-026-01293-2","DOIUrl":"https://doi.org/10.1038/s41574-026-01293-2","url":null,"abstract":"<p><p>Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, defined by rapid progression, early metastasis and resistance to nearly all standard therapies. Although it accounts for less than 2% of thyroid cancers, ATC causes a disproportionate number of thyroid cancer-related deaths, with median overall survival rarely exceeding 10 months. Most patients present with unresectable or metastatic disease, leaving few curative options. The biology of ATC reflects a convergence of diverse oncogenic drivers and profound tumour plasticity. Frequent alterations in MAPK and PI3K pathways, loss of tumour suppressors and epigenetic deregulation fuel uncontrolled proliferation. A hypoxic and inflammatory microenvironment further promotes angiogenesis, immune evasion and metastatic spread. ATC cells also undergo extensive metabolic rewiring, shifting between glycolysis and oxidative phosphorylation to withstand nutrient and therapeutic stress. In parallel, stromal components, including fibroblasts, immune cells and endothelial networks, reinforce invasion and treatment resistance. In this Review, we highlight advances in the understanding of ATC biology, with a focus on driver genetic alterations, metabolic plasticity and microenvironmental interactions that underpin its exceptional aggressiveness. We also discuss how these biological insights provide a rationale for the design of multimodal therapeutic strategies urgently needed to improve outcomes for patients with ATC.</p>","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":" ","pages":""},"PeriodicalIF":39.1,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148819087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sunita M C De Sousa, Cynthia L Andoniadou, Adrian F Daly, Mônica Gadelha, Federico Gatto, Peter Kamenický, Pedro Marques, Martin Reincke, Frederique Ruf-Zamojski, Roberto Salvatori, Yutaka Takahashi, Christina Tatsi, Takako Araki, Sabrina Chiloiro, Laura Dichtel, Adriana G Ioachimescu, Susana Mallea-Gil, Dan A Niculescu, Alberto M Pereira, Ilan Shimon, John Wass, Gabriel Zada, Maria Fleseriu, Shlomo Melmed
{"title":"Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement.","authors":"Sunita M C De Sousa, Cynthia L Andoniadou, Adrian F Daly, Mônica Gadelha, Federico Gatto, Peter Kamenický, Pedro Marques, Martin Reincke, Frederique Ruf-Zamojski, Roberto Salvatori, Yutaka Takahashi, Christina Tatsi, Takako Araki, Sabrina Chiloiro, Laura Dichtel, Adriana G Ioachimescu, Susana Mallea-Gil, Dan A Niculescu, Alberto M Pereira, Ilan Shimon, John Wass, Gabriel Zada, Maria Fleseriu, Shlomo Melmed","doi":"10.1038/s41574-026-01291-4","DOIUrl":"https://doi.org/10.1038/s41574-026-01291-4","url":null,"abstract":"<p><p>Genetic testing of patients with pituitary adenomas enables delivery of genotype-based precision care. Germline testing might identify variants predisposing to formation of pituitary adenomas and, potentially, other neoplasms. These include loss-of-function variants in AIP, MEN1, CDKN1B, PRKAR1A, SDHA, SDHB, SDHC, SDHD and MAX; GPR101-containing Xq26.3 microduplications; and postzygotic gain-of-function GNAS variants. Somatic testing might help identify and manage aggressive pituitary adenoma types and very rarely encountered pituitary carcinomas. This Pituitary Society Consensus Statement provides evidence-based guidance on the clinical application of these genetic tests, focusing on germline genetic testing, with recommendations regarding genes for inclusion in panel testing, test indications, pre-test counselling, test methodologies, and the interpretation and follow-up of results. As somatic genetic testing is gradually becoming available in clinical practice, recommendations are provided regarding clinical scenarios in which somatic testing might be considered and which genes to test. The consensus group concluded that genetic testing is an increasingly valuable adjunct in the assessment and management of people with pituitary adenomas. When indicated, genetic testing should ideally be undertaken within a multidisciplinary team comprising endocrine, genetic and laboratory expertise to ensure high-quality testing and safe and effective result interpretation and follow-up.</p>","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":" ","pages":""},"PeriodicalIF":39.1,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148819074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew Dauber, Moira S Cheung, Julie Hoover-Fong, Svein Otto Fredwall, Moeenaldeen AlSayed, Silvio Boero, Alistair D Calder, Valérie Cormier-Daire, Virginia Fano, Takuo Kubota, Philip Kunkel, Juan Llerena Junior, Mohamad Maghnie, Geert Mortier, Noriyuki Namba, Amaka C Offiah, Keita Okada, Sérgio B Sousa, Ravi Savarirayan
{"title":"Diagnosis of hypochondroplasia: international Delphi consensus recommendations.","authors":"Andrew Dauber, Moira S Cheung, Julie Hoover-Fong, Svein Otto Fredwall, Moeenaldeen AlSayed, Silvio Boero, Alistair D Calder, Valérie Cormier-Daire, Virginia Fano, Takuo Kubota, Philip Kunkel, Juan Llerena Junior, Mohamad Maghnie, Geert Mortier, Noriyuki Namba, Amaka C Offiah, Keita Okada, Sérgio B Sousa, Ravi Savarirayan","doi":"10.1038/s41574-026-01296-z","DOIUrl":"https://doi.org/10.1038/s41574-026-01296-z","url":null,"abstract":"<p><p>Hypochondroplasia is a skeletal dysplasia caused by pathogenic variants in FGFR3 and characterized by disproportionate short stature and relative macrocephaly. Diagnostic uncertainty remains common, particularly in early childhood and in individuals with mild or atypical presentations, leading to delayed diagnosis, inconsistent management, and challenges in counselling and care planning. Individuals can be affected by medical complications and psychosocial consequences and have unmet needs for multidisciplinary care. To address these unmet needs, an international, multidisciplinary panel of experts and patient representatives convened to develop consensus-based diagnostic recommendations using a modified two-stage Delphi approach, with a predefined consensus threshold of 70% of respondents rating statements ≥70 (on a scale of 0 to 100). The panel integrated clinical, anthropometric, radiographic, neuroimaging and genetic criteria to define diagnostic categories that can be applied across diverse health-care settings globally. Major and minor diagnostic criteria are proposed, alongside guidance on the appropriate use of molecular testing, radiographic evaluation and brain magnetic resonance imaging. These recommendations provide a practical framework to help standardize timely and accurate diagnosis of hypochondroplasia in clinical practice and research.</p>","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":" ","pages":""},"PeriodicalIF":39.1,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Appetite-suppressing effects of GIPR agonism and antagonism work through different brain regions","authors":"Olivia Tysoe","doi":"10.1038/s41574-026-01298-x","DOIUrl":"10.1038/s41574-026-01298-x","url":null,"abstract":"","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"22 10","pages":"571-571"},"PeriodicalIF":39.1,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Endocannabinoids and related lipids in host metabolism-gut microbiome signalling.","authors":"Cristoforo Silvestri, Vincenzo Di Marzo","doi":"10.1038/s41574-026-01289-y","DOIUrl":"https://doi.org/10.1038/s41574-026-01289-y","url":null,"abstract":"<p><p>Over the past two decades, it has become clear that the two endocannabinoids, anandamide and 2-arachidonoyl-glycerol, are only the tip of an iceberg of a larger signalling system composed of hundreds of chemically similar fatty acid derivatives, including 2-monoacylglycerols, N-acylethanolamines and other N-acylamines. Unlike the endocannabinoids, these lipids only seldom bind the two cannabinoid receptors, of which CB1 is now recognized as a major player in both the central and peripheral control of energy metabolism. They modulate instead the activity of other G-protein-coupled receptors, as well as of ligand-activated ion channels and nuclear receptors, which also regulate energy intake, accumulation and expenditure. Bacteria inhabiting the gut as part of the intestinal microbiome also produce endocannabinoid-like molecules capable of activating host receptors in vitro. These discoveries led to current research into potential bi-directional communication between this 'extended endocannabinoid system', or endocannabinoidome, and the gut microbiome. Ongoing studies are investigating how this axis might control energy metabolism, particularly in response to diet.</p>","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":" ","pages":""},"PeriodicalIF":39.1,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jun Liao, Lukas Farbiak, Daniel J. Siegwart, Chuang Liu
{"title":"mRNA-LNP therapeutics for obesity: weight loss with metabolic repair","authors":"Jun Liao, Lukas Farbiak, Daniel J. Siegwart, Chuang Liu","doi":"10.1038/s41574-026-01297-y","DOIUrl":"10.1038/s41574-026-01297-y","url":null,"abstract":"Obesity involves dysfunction in metabolic tissues that is not always fully corrected by weight loss. An mRNA-lipid nanoparticle platform might offer a programmable approach for in situ production of therapeutic proteins directly in target tissues, enabling endocrine signalling, adipose remodelling and multi-pathway metabolic regulation.","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"22 10","pages":"569-570"},"PeriodicalIF":39.1,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leonardo V. M. de Assis, Richard M. Blay, Madilyn Coles, Taylah L. Gaynor, Mathilde Palmier, Aswathi Surendran, Elpida Vounzoulaki, Ingrid M. Wagnon, Thilo S. Chillon
{"title":"Leadership for the postdoctoral to independent investigator transition","authors":"Leonardo V. M. de Assis, Richard M. Blay, Madilyn Coles, Taylah L. Gaynor, Mathilde Palmier, Aswathi Surendran, Elpida Vounzoulaki, Ingrid M. Wagnon, Thilo S. Chillon","doi":"10.1038/s41574-026-01294-1","DOIUrl":"10.1038/s41574-026-01294-1","url":null,"abstract":"The transition from postdoctoral researcher to independent investigator is marked by complex decision-making and uncertainty. At the Danish Diabetes and Endocrine Academy Postdoc Summit 2025, we discussed these challenges, as well as strategies to support this transition.","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"22 10","pages":"567-568"},"PeriodicalIF":39.1,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Birgitte R Kornum, Alberte Wollesen Breum, Zuzanna Mincikiewicz, Stine Knudsen-Heier
{"title":"Therapeutic potential of targeting the orexin (hypocretin) system in sleep disorders.","authors":"Birgitte R Kornum, Alberte Wollesen Breum, Zuzanna Mincikiewicz, Stine Knudsen-Heier","doi":"10.1038/s41574-026-01277-2","DOIUrl":"https://doi.org/10.1038/s41574-026-01277-2","url":null,"abstract":"<p><p>Sleep is emerging as a key health topic in modern society. The prevalence of and focus on sleep-wake disorders is increasing, which has led to a large interest from the pharmaceutical industry to develop new treatments targeting sleep biology (that is, drugs that have the potential to mimic normal sleep-wake physiology). The orexin (also known as hypocretin) system is one of the key targets and regulators of sleep and wakefulness. In this Review, we will discuss the mechanisms by which loss of orexin signalling is involved in narcolepsy type 1 and whether loss and/or disruption of orexin signalling might have a role in other sleep disorders such as narcolepsy type 2, idiopathic hypersomnia and obstructive sleep apnoea. We will also describe current and emerging therapies for sleep disorders involving orexin, such as orexin receptor antagonists for insomnia and orexin receptor agonists for narcolepsy.</p>","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":" ","pages":""},"PeriodicalIF":39.1,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Claes Ohlsson, Lina Lawenius, Louise Grahnemo, Klara Sjögren
{"title":"Links between bone fractures and the gut microbiota.","authors":"Claes Ohlsson, Lina Lawenius, Louise Grahnemo, Klara Sjögren","doi":"10.1038/s41574-026-01286-1","DOIUrl":"https://doi.org/10.1038/s41574-026-01286-1","url":null,"abstract":"<p><p>As populations age worldwide, the incidence of fractures is increasing, leading to considerable disease burden and increased health-care costs. Bone mineral density (BMD), bone quality and muscle function are major contributors to fracture risk, with muscle function having a critical role in preventing falls. The gut microbiota is well established as a regulator of these parameters in rodents, with the immune system and short-chain fatty acids acting as key mediators of these effects. First-generation probiotic interventions have demonstrated modest effects on BMD in clinical trials. In humans, the association between the gut microbiota and muscle mass, muscle function and fracture risk seems to be more robust than the correlation between gut microbiota and BMD. Future research should prioritize the development of more targeted gut microbiota-based interventions, including second-generation probiotics, personalized dietary strategies, synbiotics, postbiotics and species-specific antibiotics with the potential to enhance both BMD and muscle function, thereby reducing risk of fractures.</p>","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":" ","pages":""},"PeriodicalIF":39.1,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}